Intraplaque and Cellular Distribution of Dextran-Coated Iron Oxide Fluorescently Labeled Nanoparticles: Insights Into Atherothrombosis and Plaque Rupture.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Atherosclerosis, Periodontal Disease, and Treatment with Resolvins.Current atherosclerosis reports · 2017
   Review
2. Synthesis of europium-doped VSOP, customized enhancer solution and improved microscopy fluorescence methodology for unambiguous histological detection.Journal of nanobiotechnology · 2017
   Article

Corrections and comments

• Comment on
  Atheroma Susceptible to Thrombosis Exhibit Impaired Endothelial Permeability In Vivo as Assessed by Nanoparticle-Based Fluorescence Molecular Imaging.2017

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as